Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan.

Next Previous
Search
Trial Profile

A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan.

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 05 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BGT 226 (Primary)
  • Indications Gallbladder cancer; Gastric cancer; Rectal cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 21 Sep 2018 Status changed from completed to suspended.
    • 05 May 2010 Actual number of patients (57) added as reported by ClinicalTrials.gov record.
    • 05 May 2010 Actual end date (1 MAr 2010) added as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top